Thyrocare Technologies has announced several key corporate decisions following its Board meeting on May 7, 2026. Highlights include a final dividend recommendation of Rs. 7.00 per share for the 2025-26 financial year, the appointment of new statutory and cost auditors, and the re-appointment of its leadership. Additionally, the Board approved a capital infusion of up to Rs. 5.50 crores into its subsidiary, Think Health Diagnostics, to support operational growth.
Dividend and Financial Performance
The Board has recommended a final dividend of Rs. 7.00 per equity share for the financial year ending March 31, 2026, pending shareholder approval at the upcoming Annual General Meeting. This follows an interim dividend of Rs. 7.00 per share (pre-bonus adjustment) already paid, bringing the total dividend for the year to Rs. 9.33 per share on a post-bonus adjustment basis.
Leadership and Governance Changes
Mr. Rahul Franklin Guha has been re-appointed as the Chairman, Managing Director, and Chief Executive Officer of the company for a new five-year term, effective from May 4, 2027, to May 3, 2032. Simultaneously, the company has appointed Mr. Uday Patel Kadam and Mr. Gaurav Verma as Additional Directors in the category of Non-Executive, Non-Independent Directors, effective May 8, 2026. The Board also noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah from their respective directorships.
Auditor Appointments
Following the recommendation of the Audit Committee, the company has appointed M/s. Price Waterhouse Chartered Accountants LLP as the new Statutory Auditor for a five-year term, succeeding M/s. M S K A & Associates LLP upon the conclusion of the 26th Annual General Meeting. Additionally, M/s. Jitender Navneet & Co. has been appointed as the Cost Auditor for the 2026-27 financial year.
Investment in Think Health Diagnostics
To bolster its expansion in the healthcare diagnostics sector, the Board approved an investment of up to Rs. 5.50 crores via subscription to equity shares of Think Health Diagnostics Private Limited. This wholly-owned subsidiary focuses on building a dedicated platform for high-volume, affordable diagnostic testing. The funds are earmarked for capital expenditure and general working capital requirements.
Memorandum of Association Update
The company is set to modernize its Memorandum of Association to align with the Companies Act, 2013. Furthermore, the Board aims to broaden the company’s business scope by including a wider range of activities within the healthcare and diagnostics ecosystem, such as managing digital health platforms and dealing in medical consumables and diagnostic equipment.
Source: BSE
